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Abstract
Objective:  To determine plasma apolipoprotein M (apoM) levels and other lipid profiles in
hepatocellular carcinoma (HCC) patients compared to other chronic liver diseases and normal
subjects.
Materials and methods: 36 HCC, 68 chronic hepatitis, 29 liver cirrhosis patients and 64 normal
controls were subjected in the present study. Serum lipids, lipoproteins, apolipoprotein AI (apoAI)
and apoB were determined by the conventional methods. Plasma apoM levels were semi-
quantitatively determined by both dot-blotting and western blotting analysis.
Results: Serum levels of triglycerides (TG), HDL-cholesterol, apoAI and lipoprotein (a) (Lp(a))
were significantly lower in the HCC patients than in the normal subjects, whereas there were no
obvious differences on serum total cholesterol, LDL-cholesterol and apoB between HCC patients
and normal subjects. However, plasma apoM levels in HCC patients were significantly increased
than those in the normal subjects, but lower than those in the chronic hepatitis and cirrhosis
patients.
Conclusion: It is concluded that serum TG, apoAI, HDL-C and Lp(a) were significantly decreased
in HCC patients than in controls, whereas plasma apoM levels were significantly increased in the
HCC patients. Decreased serum TG, apoAI, HDL-C and Lp(a) may reflect the liver damage in HCC
patients, whereas the clinical significance of increased plasma apoM levels in relation to HCC is not
clear.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most com-
mon fatal malignant tumors in China and in other South-
east Asian countries [1,2], which has been attributed to
the high incidence of hepatitis B infection [3-5]. Most
plasma apolipoproteins, endogenous lipids and lipopro-
teins are synthesized by liver, which depends on the integ-
rity of cellular liver functions. Under normal
physiological conditions, liver ensures homeostasis of
lipid and lipoprotein metabolism. It has been demon-
strated that plasma lipid profiles could be changed in the
HCC patients [6]. In majority of the reports, plasma levels
of triglycerides (TG), cholesterol, free fatty acids (FFA),
high-density lipoprotein (HDL), low-density lipoproteins
(LDL), lipoprotein (a) (Lp(a)), apolipoprotein AI (apoAI)
and apoB were slightly to significantly decreased in the
HCC patients, however, in certain cases plasma levels of
TG and Lp(a) might even increase [7-9]. It has been sug-
gested that analysis of plasma levels of lipids, lipoproteins
and apolipoproteins in HCC patients may reflect the sta-
tus of hepatic cellular impairments [8], and decreased
serum levels of cholesterol and apoAI may indicate a poor
prognosis [7-9].
As apoM is exclusively expressed in hepatocytes and kid-
ney tubular cells [10,11], the plasma apoM levels may also
be changed in the HCC patients and in other liver dis-
eases. In the present study we examined plasma levels of
lipids, lipoproteins, apoAI, apoB and apoM in the HCC
patients compared with the other liver diseases and nor-
mal subjects.
Materials and methods
Patients and controls
36 surgical operated HCC patients (29 men and 7 women,
aged from 29 to 83 years old, mean age is 57 years old),
68 chronic hepatitis patients (53 men and 15 women, 16–
72 years old, mean age is 37 years old) and 29 liver cirrho-
sis patients (21 men and 8 women, 38–79 years old, mean
age is 52 years old) were subjected in the present study. 64
normal subjects (44 men and 20 women, 28–71 years old,
mean age is 43 years old) were selected as controls. All
normal subjects were confirmed by blood biochemical
tests, virus tests and B-type ultrasonic inspection to
exclude hepatitis or other liver diseases. The present study
was approved by the local ethics committee.
Determinations of serum lipid profile and plasma apoM 
levels
Serum levels of TG, TC, HDL-cholesterol and LDL-choles-
terol were determined by enzymatic method, and serum
levels of apoAI and apoB were determined by the turbidity
method. All samples were carried out on the Beckman LX-
420 automatic biochemistry analyzer. Plasma apoM levels
were semi-quantitatively determined by both dot-blotting
and western blotting analysis with a specific rabbit anti-
human apoM antibody [12]. In brief for dot blotting anal-
ysis, 2 μl plasma samples were applied to the Hybond-C
membrane in triplicate. All samples were applied in the
same membrane. The membrane was quenched in TBS
buffer in the presence of 4% Tween and 3% BSA for 4 hrs,
and then incubated with 1:4000 diluted primary antibod-
ies at 4°C overnight. After washing 4 times with TBS
buffer, it was incubated with AP conjugated goat anti-rab-
bit IgG antibody (Southern Biotech, USA) for 4 hrs at
room temperature, and then visualized by NBT/BCIP
method (Sino-American Biotechnology Co. Shanghai,
China), according to the manufacturer's instruction.
Plasma apoM levels were also determined by the western
blotting analysis. 5 μl plasma was fractionated by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE), trans-
ferred to nitrocellulose membrane, and incubated with
rabbit against human apoM polyclonal antibodies. AP
conjugated goat anti-rabbit IgG antibody was used as the
secondary antibody. The relative amount of apoM was
analyzed by a scanner using Quantity One (Version4.2.1,
Bio-Rad Laboratories, Hercules, USA) and represented as
volume (intensity/mm2).
Statistical analysis
Statistical analysis was performed with SPSS13.0 software.
Differences of serum lipid profiles and plasma apoM lev-
els between patients and controls were analyzed by the
one-way ANOVA followed the Newman-Keuls multiple
comparison tests. Data are expressed as means ± SE. A p
value less than 0.05 (P < 0.05) was considered as signifi-
cant.
Results
Serum lipid profiles in different liver diseases and in 
controls
As shown in table 1, both serum levels of Lp (a) and apoAI
were significantly decreased in the patients suffered from
HCC, chronic hepatitis or liver cirrhosis. And in HCC
patients, serum levels of triglycerides and HDL-C were
also statistically significantly decreased compared with
those in normal subjects. There were no obvious changes
on serum cholesterol, LDL-cholesterol and apoB between
HCC patients and normal subjects. However, in the
patients with liver cirrhosis, serum levels of TG and HDL-
cholesterol were even higher than those in the controls.
Plasma apoM levels in HCC, chronic hepatitis, liver 
cirrhosis and normal subjects
As shown in Fig 1, the plasma relative apoM levels in HCC
patients were 712.87 ± 345.98 Int/mm2, which was signif-
icantly higher than those in the normal subjects (433.70
± 79.53 Int/mm2) (t = 3.399, P < 0.05). ApoM levels were
even higher in the patients suffered from chronic hepatitis
and cirrhosis, the later with highest plasma apoM levels.Lipids in Health and Disease 2008, 7:25 http://www.lipidworld.com/content/7/1/25
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In the present study plasma apoM levels were semi-quan-
tified by both dot-blotting and western blotting analysis,
and similar results were obtained from both methods.
Discussion
In the present study it is demonstrated that both apoAI
and Lp(a) were significantly decreased in the patients suf-
fered from either HCC, chronic hepatitis or liver cirrhosis,
which indicates that apoAI and Lp(a) can be considered as
a stable index of liver damage. Interestingly in the present
study, we demonstrated that plasma apoM levels were sig-
nificantly increased in the HCC patients, whereas serum
TG, apoAI, HDL-C and Lp(a) were significantly lower in
HCC patients than in controls. Decreased serum TG,
apoAI, HDL-C and Lp(a) may reflect the liver damage in
HCC patients, however, the clinical significance of
Table 1: Lipid profiles in normal subjects and in the patients suffered from hepatocellular carcinoma (HCC), chronic hepatitis or liver 
cirrhosis
Parameter Means ± SD F value P value vs. Normal vs. HCC vs. CH
T-Chol (mmol/L) 4.761 0.003
Normal (n = 64) 4.65 ± 0.87
HCC (n = 36) 4.41 ± 1.85 0.439
Chronic hepatitis (n = 68) 4.63 ± 1.00 0.929 0.480
Liver cirrhosis (n = 29) 5.70 ± 2.62 0.002 0.001 0.001
TG (mmol/L) 19.337 0.000
Normal 1.59 ± 0.81
HCC 1.12 ± 0.57 0.001
Chronic hepatitis 2.15 ± 0.64 0.000 0.000
Liver cirrhosis 1.90 ± 0.64 0.044 0.000 0.101
HDL-C (mmol/L) 6.139 0.001
Normal 1.30 ± 0.36
HCC 1.06 ± 0.45 0.043
Chronic hepatitis 1.27 ± 0.55 0.816 0.064
Liver cirrhosis 1.66 ± 0.99 0.005 0.000 0.003
LDL-C (mmol/L) 0.896 0.444
Normal 2.73 ± 0.66
HCC 2.37 ± 0.79
Chronic hepatitis 3.48 ± 6.04
Liver cirrhosis 2.73 ± 1.08
Lp(a) (mg/L) 7.770 0.000
Normal 159.41 ± 123.06
HCC 87.64 ± 56.39 0.000
Chronic hepatitis 89.80 ± 54.75 0.000 0.910
Liver cirrhosis 101.97 ± 119.23 0.006 0.537 0.555
ApoAI (g/L) 7.200 0.000
Normal 1.24 ± 0.16
HCC 1.13 ± 0.24 0.021
Chronic hepatitis 1.08 ± 0.26 0.000 0.352
Liver cirrhosis 1.03 ± 0.31 0.000 0.124 0.384
ApoB (g/L) 1.669 0.175
Normal 1.07 ± 0.37
HCC 0.90 ± 0.48
Chronic hepatitis 1.02 ± 0.28
Liver cirrhosis 1.07 ± 0.53
ApoM (Int/mm2) 80.657 0.000
Normal 433.70 ± 79.53
HCC 712.87 ± 345.98 0.017
Chronic hepatitis 1318.77 ± 752.34 0.000 0.000
Liver cirrhosis 2252.46 ± 790.45 0.000 0.000 0.000Lipids in Health and Disease 2008, 7:25 http://www.lipidworld.com/content/7/1/25
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increased plasma apoM levels in relation to HCC is not
clear.
The patients with HCC frequently have other liver dis-
eases such as chronic hepatitis and/or cirrhosis. All these
conditions (hepatitis and cirrhosis of the liver) are often
associated with plasma lipid and lipoprotein aberrations
[13]. In the present study we demonstrated that serum TG
was significantly decreased in HCC patients than in the
normal subjects, which was similar to the reported data
that plasma TG decreased by 20–30% in the patients with
HCC [14]. However, Alsabti, et al., [15] reported that
serum TG in HCC patients were even increased when
compared to those with cirrhosis. Ooi, et al., [8] reported
that plasma TG levels in HCC patients were not signifi-
cantly different compared with the controls. These results
emphasize the fact that changes of plasma lipid profile
may not always imply the presence of HCC and one need
to exercise caution in interpreting these results.
About 80% endogenous cholesterol are synthesized in the
hepatocellular microsomes that contain cholesterol syn-
thesis enzymes [16,17]. In HCC and chronic liver diseases
the synthesis and metabolism of cholesterol are impaired.
It leads to a decrease in plasma cholesterol levels
[8,14,18,19]. In the present study we demonstrated that
total cholesterol, apoB and HDL-cholesterol were
decreased in HCC patients, and there were no obvious
changes on serum LDL-cholesterol in HCC patients com-
pared with controls. Ahaneku, et al., [19] analyzed HDL-
fraction levels including HDL-C, HDL-phospholipids
(HDL-PL) and the ratio of HDL-C/HDL-PL, in HCC
patients and compared with the controls. They found that
plasma HDL-C, HDL-PL and HDL-C/HDL-PL were signif-
icantly lower in HCC patients than those in the controls.
Motta, et al., [14] studied 40 patients with HCC, and eval-
uated the LDL-C, HDL-C. In patients with HCC, LDL-C
level was significantly lower than in the controls. Kanel, et
al., [20] reported that patients with primary or metastatic
liver cancer had strikingly decreased HDL-C. Ooi, et al.,
[8] suggested that HDL-C may be clinically useful to
reflect the pathologic conditions, and can be used to eval-
uate the severity of liver diseases.
Liver represents the main site of Lp(a) synthesis [21-23].
Half-life of Lp(a) is about 3.3–3.9 days in human plasma
[24], which is influenced in the early stage when liver
function was impaired [21]. Lp(a) is synthesized and
metabolized independently of other plasma lipoproteins,
and Lp(a) level is not influenced by various dietary
manipulations [25]. It has been reported that serum Lp(a)
were significantly lower in the HCC patients [26,27]. The
similar results were obtained in the present study. How-
ever, Geiss, et al., [28] observed patients with acute hepa-
titis showed a marked increase in Lp(a) concentration,
i.e., 7 mg/dL in acute stage and 32 mg/dL in the convales-
cence of the disease. Basili, et al., reported that Lp(a)
could also be increased in the patients suffered from HCC
together with cirrhosis [29]. It has been demonstrated that
Lp(a) together with ferritin and alpha-fetoprotein could
be a sensitive and early marker to evaluate liver function
[14]. As Lp(a) has positive correlation with the hepatic
status, it has been suggested that Lp(a) could be consid-
ered as a index of liver function [14,23,30].
Liver is the main organ for the synthesis, storage, transpor-
tation and degradation of certain apolipoproteins [31].
Each protein may be influenced by liver disease in a differ-
ent way, and serum lipoprotein concentrations with faster
turn-over are more reduced with respect to those with
slower turn-over [32]. It is reported that serum concentra-
tions of apoAI and apoAII were significantly lower in the
patients suffered from HCC [7,9], but an increase in the
proportion of proapoAI was found in patients with HCC
[33]. In the present study we demonstrated that both
apoAI and apoB were significantly decreased in HCC
patients compared with the normal subjects. Decreased
serum apoAI and apoB levels may reflect the liver damage
in HCC patients, as most HCC patients are companied
with chronic liver injury. Interestingly in the present study
we demonstrated that plasma apoM levels were signifi-
cantly increased in the HCC patients than in controls, and
apoM levels were even higher in the patients suffered from
Comparisons of plasma apoM levels in HCC patients, chronic  hepatitis, liver cirrhosis and in controls Figure 1
Comparisons of plasma apoM levels in HCC patients, 
chronic hepatitis, liver cirrhosis and in controls. 
Plasma apoM levels were determined by dot blotting analysis. 
Data are represented as means ± SE and it expressed as the 
intensity/mm2 that was analyzed by the software of Quantity 
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chronic hepatitis and liver cirrhosis, which may relate to
the aberration of host immune system. The detailed
mechanism needs further investigation.
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